Our CEO, Kristina Torfgård, at BioStock studio.

Date: 2022-06-03

Kristina visited Biostock's studio to talk about how Alzinova differs from other companies developing treatments for Alzheimer's disease. She gave an update on the company's main candidates ALZ-101 and ALZ-201, and explained more about how the proceeds from the ongoing rights issue will be used.

Check out the short video below and visit this page for more information about the rights issue.